Dimetrio is hormones of gonads and medicaments used at pathology of genitals. Progestogens. Shown for treatment of endometriosis.

Structure

1 tablet, coated, contains

• diyenogest of 2 mg;
• excipients: lactose, starch corn, (K-30), starch sodium (type A), magnesium stearate, water the cleaned film cover: a gipromelloz (E 464), hydroxypropyl cellulose (E 463), talc (E 553b), the cottonseed oil hydrogenated the titan dioxide (E 171), the water purified.

Contraindication

Drug Dimetrio should not be used in the presence of any of following states or diseases. If any of these states or diseases arises for the first time during use of the medicine Dimetrio, administration of medicament should be stopped immediately.

• a venous thrombembolia in an active form;
• arterial or cardiovascular diseases in the anamnesis (for example a myocardial infarction, cerebrovascular an event, coronary heart disease);
• diabetes with defeat of vessels.

to Accept

on 1 tablet daily without interruption in administration of medicament approximately at the same time, washing down with a small amount of liquid. A pill can be taken irrespective of meal.

should take the Pill regularly, irrespective of menstrual bleeding. As soon as tablets from one packing ended, to begin to take a pill from the following packing, without taking a break in use of medicine.

does not have experience of treatment of Dimetrio of patients with endometriosis longer than 15 months.

Administration of medicament can be begun with

in any day of a menstrual cycle.

Use of any hormonal contraceptives should be stopped prior to therapy by the medicine Dimetrio. If contraception is necessary, it is necessary to apply in addition a non-hormonal method of prevention of pregnancy (for example, a barrier method).

Feature of application

As Dimetrio - the medicine containing only progestogen is considered that special cautions and security measures on use of progestinovmisny medicines also concern the medicine Dimetrio though not all cautions and precautionary measures are based on the corresponding results of clinical trials of this medicine.

At deterioration or the first emergence of any of the states/risk factors provided below, the analysis of a ratio risk/advantage before the beginning or continuation of use of the medicine Dimetrio has to be carried out individually.

Heavy uterine bleedings

Uterine bleeding, for example, at women with an adenomyosis of a uterus or a leiomyoma of a uterus can increase at use of the medicine Dimetrio. If bleeding it is expressed and does not stop for a long time, it can lead to anemia (in certain cases - heavy). In that case it is necessary to consider a question of the termination of administration of drug.

Pregnant

is not recommended to be applied to pregnant women as there is no need to treat endometriosis during pregnancy.

by

for application for children before menarche.

Drivers

did not observe influence on ability to steer motor transport and to operate mechanisms at the patients taking the medicaments containing diyenogest.

Overdose

Research of acute toxicity, carried out with Diyenogest, did not point out risk of development of acute side reactions in case of inadvertent reception of several daily therapeutic doses. No specific antidotes exist. Use of 20 - 30 mg of the diyenogest to day (that is 10 - 15 times higher, than a dose in a medicine Dimetrio tablet) within more than 24 weeks were transferred very well.

Side effects

Metabolism and disbolism: increase in body weight, decrease in body weight, the increased appetite.

Mental disorders: suppressed mood, sleep disorder, nervousness, decrease in a libido, changes of mood, concern, depression, lability of mood.

from nervous system: headache, migraine, violation of vegetative regulation, violation of attention.

from organs of sight: xerophthalmus.

Storage conditions

Are absent special requirements for medicine storage.